Cure IBM Research Fund at TMA Grant
The Cure IBM Research Fund at TMA Grant from The Myositis Association supports in-depth basic science research into the molecular and cellular mechanisms of inclusion body myositis.
Funder: The Myositis Association
Due Dates (Anticipated): May 2027 (Letter of Intent) | June 2027 (Full application) | July 2027 (Cure IBM Research Fund full application)
Funding Amounts: Up to $105,000 per award; 12–24 month funding period; includes $5,000 for travel to research and patient conferences.
Summary: Supports foundational and mechanistic research into the biological basis of inclusion body myositis (IBM), prioritizing basic science studies in affected muscle tissue.
Key Information: All dates are projected; confirm details on the program page before applying.
Description
The Cure IBM Research Fund at TMA Grant, administered by The Myositis Association (TMA), aims to accelerate scientific understanding of inclusion body myositis (IBM) by funding innovative basic science and mechanistic research. The grant is designed to support projects investigating the molecular and cellular changes in skeletal muscle that drive IBM’s causes, pathophysiology, and disease progression. Emphasis is placed on hypothesis-driven studies exploring RNA processing, mitochondrial dysfunction, immune mechanisms, stromal remodeling, and intercellular signaling, with the goal of generating foundational knowledge that can inform future studies and potential therapies. This opportunity is part of TMA’s ongoing commitment to advancing research into myositis and related rare muscle diseases.
